Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Author(s) -
Hyman B. Muss,
Donald A. Berry,
Constance Cirrincione,
Maria Theodoulou,
Ann M. Mauer,
Alice B. Kornblith,
Ann H. Partridge,
Lynn G. Dressler,
Harvey Jay Cohen,
Heather P. Becker,
Patricia A. Kartcheske,
Judith Wheeler,
Edith A. Perez,
Antonio C. Wolff,
Julie R. Gralow,
Harold J. Burstein,
Ahmad Mahmood,
Gustav Magrinat,
Barbara A. Parker,
Ronald D. Hart,
Debjani Grenier,
Larry Norton,
Clifford A. Hudis,
Eric P. Winer
Publication year - 2009
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0810266
Subject(s) - medicine , capecitabine , breast cancer , oncology , chemotherapy , adjuvant chemotherapy , stage (stratigraphy) , adjuvant , cancer , clinical trial , gynecology , colorectal cancer , paleontology , biology
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant. We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom